IDYA (IDEAYA Bio) חוב לטווח ארוך

Geopolitical tensions are undermining the international clinical trial networks of IDEAYA Biosciences (IDYA), blocking the registration of targeted therapies. The company's long-term obligations demonstrate financial stability, where the 0.02 metric determines this level. Risks are mitigated by recruiting leading oncology researchers with high option-based incentives and implementing robotic platforms for accelerated molecule screening.

This indicator aggregates all credit obligations with a maturity of more than one year, allowing for an assessment of long-term financial stability and the cost of borrowed capital. By analyzing the long-term liability statistics of the issuer, an investor can compare borrowing rates with the pace of oncology drug development at IDEAYA Biosciences (IDYA) to ensure that the debt load does not hinder the funding of clinical trials.